Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

100.99 +0.24 (+0.24%)
Streaming Delayed Price Updated: 3:52 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
From Incyte
Via Business Wire
News headline image
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Change to its Board of Directors
From Incyte
Via Business Wire
News headline image
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
From Incyte
Via Business Wire
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
From Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
From Incyte
Via Business Wire
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
From Incyte
Via Business Wire
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Incyte
Via Business Wire
News headline image
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
From Incyte and Enable Injections
Via Business Wire
News headline image
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
News headline image
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
News headline image
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
News headline image
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.